US free shipping over $150 · Exact worldwide rate at checkout · Crypto-only checkout guide — Shop now
T
Titan PeptideResearch-grade nasal sprays

Ozempic vs retatrutide · incretin receptor comparison · research use only

Ozempic vs retatrutide — branded GLP-1 versus investigational triple agonist.

Ozempic is the Novo Nordisk brand name for semaglutide approved for type 2 diabetes — a once-weekly subcutaneous injection at 0.5–2.0 mg that targets the GLP-1 receptor with high selectivity and established one of the most successful cardiovascular-outcomes profiles in the history of diabetes medicine (SUSTAIN-6: −26% MACE, Marso et al. NEJM 2016;375:1834-1844). Retatrutide is a structurally distinct investigational compound: a triple GIP/GLP-1/glucagon receptor agonist in Phase 3 trials, with TRIUMPH-4 reporting ~28.7% mean weight loss at 68 weeks and TRIUMPH-1 reporting up to ~30% at 104 weeks — approximately double the weight reduction seen with Ozempic at its highest approved dose. This page is a research-context pharmacology comparison. Titan Peptide Lab supplies retatrutide as a research-use-only compound; Titan does not sell Ozempic (semaglutide) and does not position retatrutide as a clinical substitute for any prescription medication. Neither compound is evaluated here as a treatment recommendation.

Retatrutide research vial — $199.99Retatrutide mechanism explained

Receptor targeting: Ozempic targets one receptor, retatrutide targets three

Ozempic (semaglutide) is a selective GLP-1 receptor agonist — its entire pharmacology runs through a single receptor. GLP-1R activation in the pancreas potentiates glucose-dependent insulin secretion; in the brain it suppresses appetite; in the gut it slows gastric emptying. That single receptor is responsible for all the weight and glucose effects seen in clinical trials. Retatrutide adds two receptor arms: GIP receptor (~8.9× relative potency vs GLP-1 reference) and glucagon receptor (~0.3× relative potency). The GIP arm improves insulin potentiation and may favorably influence adipogenesis. The glucagon arm elevates hepatic glucose output (a dual-edged mechanism) and — critically — increases thermogenesis and energy expenditure. Adding that third receptor is the mechanistic explanation for why TRIUMPH efficacy data substantially exceeds STEP data.

Retatrutide mechanism in detail →

Clinical trial weight-loss data: SUSTAIN/STEP vs TRIUMPH

Ozempic at 2.0 mg (the highest diabetes-approved dose): SUSTAIN-11 reported approximately 5.4% body weight reduction. Wegovy (semaglutide 2.4 mg, the obesity-approved dose) achieved approximately 14.9% in STEP-1 (Wilding et al. NEJM 2021;384:989-1002, n=1,961, 68 weeks). Retatrutide Phase 3 (TRIUMPH-4, published December 2025): ~28.7% mean weight reduction at 68 weeks at the 12 mg dose. TRIUMPH-1 (published May 21 2026, n=2,339): up to ~30% at 104 weeks. These are not head-to-head trials — populations, durations, and titration schedules differ — but the approximate doubling of magnitude reflects the receptor-count progression: single GLP-1 agonism (~15%) → dual GIP+GLP-1 (~22%) → triple GIP+GLP-1+glucagon (~28–30%).

TRIUMPH Phase 3 timeline →

Half-life and dosing: both weekly, similar pharmacokinetics

Semaglutide (Ozempic) achieves its ~7-day half-life through C18 fatty diacid albumin-binding acylation. Retatrutide achieves its ~6-day half-life through a longer C20 fatty diacid modification — similar strategy, slightly shorter half-life, both enabling once-weekly dosing. The practical PK profile is comparable: both are administered weekly, both accumulate over ~5 weeks to steady state, and both produce prolonged pharmacological activity from a single dose. This contrasts sharply with liraglutide (~13h, once-daily) and short-acting GLP-1 agonists. The weekly dosing of both makes them directly comparable in any research study design that involves administration frequency.

Retatrutide half-life reference →

Tolerability: retatrutide GI burden vs Ozempic benchmark

GLP-1 receptor agonism produces a class-wide GI adverse-event profile (nausea, vomiting, diarrhea, constipation) that is dose-dependent and front-loaded during titration. For Ozempic/Wegovy, nausea rates in STEP-1 reached approximately 44% vs 16% placebo. In the retatrutide TRIUMPH Phase 2 data (Jastreboff NEJM 2023;389:514-526, PMID 37366315), nausea was reported at approximately 28% — lower than semaglutide's benchmark despite greater efficacy. The proposed mechanism is that GIP receptor agonism, which is additive in the retatrutide molecule, may counteract some of the GI effects of GLP-1R activation. The glucagon arm introduces a separate signal: dose-dependent heart rate elevation that is not a feature of semaglutide and is being monitored in the TRIUMPH safety data.

Retatrutide side effects reference →

Regulatory status: FDA-approved vs investigational (not interchangeable)

Ozempic is FDA-approved (June 2017) for type 2 diabetes management at 0.5, 1.0, and 2.0 mg weekly. It is a prescription medication available through licensed pharmacies and prescribers under the standard clinical supply chain. Retatrutide is investigational — as of July 2026, Phase 3 trials are complete or ongoing, Eli Lilly has announced Breakthrough Therapy Designation, and no NDA has been publicly filed with FDA. Titan supplies retatrutide only as a research-use-only lyophilized vial for in-vitro laboratory research. These are separate supply contexts: the clinical/prescription channel for Ozempic versus the RUO research-compound channel for retatrutide.

Retatrutide RUO vial →

Why researchers compare Ozempic and retatrutide

The Ozempic–retatrutide comparison has emerged because semaglutide brands (Ozempic/Wegovy) became the dominant reference point in public and clinical discussion of GLP-1-class compounds. When researchers model incretin receptor contributions — asking what is specifically attributable to GLP-1R versus GIP versus glucagon receptor activation — semaglutide (as Ozempic or Wegovy) serves as the established GLP-1-only baseline. Retatrutide adds the two additional receptor arms on top of that baseline, making it the highest-complexity incretin research model currently available. The comparison is mechanistic and pharmacokinetic, not a clinical recommendation to switch from one to the other.

Incretin peptides for obesity research →

The detail, in plain terms

Ozempic vs retatrutide — side-by-side.

Research-use comparison. All data from peer-reviewed publications or Eli Lilly/Novo Nordisk Phase 3 announcements. Retatrutide: investigational. Ozempic: FDA-approved for T2D — Titan does not stock it.

Active molecule
Retatrutide: LY3437943 (Eli Lilly). Ozempic: semaglutide (Novo Nordisk).
Receptor target(s)
Retatrutide: GIP + GLP-1 + Glucagon (triple). Ozempic: GLP-1R only (single).
GIP receptor
Retatrutide: YES (~8.9× potency). Ozempic: NO — GLP-1R only.
Glucagon receptor
Retatrutide: YES (~0.3×; thermogenesis/energy expenditure). Ozempic: NO.
Half-life / dosing
Retatrutide: ~6 days; weekly (C20 fatty diacid). Ozempic: ~7 days; weekly (C18 fatty diacid).
Phase 3 weight loss
Retatrutide: TRIUMPH-4 ~28.7% at 68wk; TRIUMPH-1 up to ~30% at 104wk (2025–2026). Ozempic 2mg: ~5.4% weight loss (T2D indication). Wegovy 2.4mg (same molecule): STEP-1 ~14.9% at 68wk (obesity).
Nausea rate
Retatrutide Phase 2: ~28%. Wegovy STEP-1: ~44% vs 16% placebo.
Heart rate signal
Retatrutide: dose-dependent HR elevation (glucagon arm). Ozempic: minimal HR effect.
FDA status
Retatrutide: investigational / Breakthrough Therapy / NDA not filed (Jul 2026). Ozempic: FDA-approved 2017 (T2D).
Titan supply
Retatrutide: lyophilized research vial, RUO, $199.99. Ozempic: NOT stocked by Titan.

head-to-head

Ozempic vs retatrutide — receptor and trial data

Mechanism and efficacy context from published Phase 3 data. Research use only.

CriterionRetatrutideOzempic (semaglutide)
Receptor target(s)GIP + GLP-1 + Glucagon (triple)GLP-1 only (single)
Drug classThird-generation incretin triple agonist (investigational)First/second-generation GLP-1 agonist (approved)
Half-life~6 days (weekly)~7 days (weekly)
Weight loss (Phase 3)~28.7% at 68wk / ~30% at 104wk (TRIUMPH)~14.9% at 68wk Wegovy 2.4mg (STEP-1 2021)
Nausea rate~28% (Phase 2)~44% Wegovy STEP-1
Heart rate effectDose-dependent elevation (glucagon arm)Minimal
Cardiovascular CVOTTRIUMPH cardiovascular data ongoingSUSTAIN-6: −26% MACE (Marso NEJM 2016)
FDA approvalInvestigational — NDA not filed (Jul 2026)Approved 2017 (T2D); Wegovy 2021 (obesity)
Titan RUO stockYes — lyophilized vial $199.99No — not stocked

Questions researchers ask

Before you order.

What is the difference between Ozempic and retatrutide?
Ozempic is the Novo Nordisk brand name for semaglutide, a GLP-1 receptor agonist approved for type 2 diabetes at 0.5–2.0 mg weekly. Retatrutide is an investigational compound that targets three receptors — GIP (~8.9×), GLP-1 (~0.4×), and glucagon (~0.3×) — compared to semaglutide's one. The triple receptor mechanism is associated with substantially greater weight-loss efficacy in Phase 3 trials: Ozempic/Wegovy (semaglutide) at its obesity-indicated 2.4 mg dose achieved approximately 14.9% weight loss at 68 weeks in STEP-1, while retatrutide achieved approximately 28.7% at 68 weeks in TRIUMPH-4. These are different pharmacological tools in different regulatory stages. This is a research comparison only.
Is retatrutide better than Ozempic?
In terms of Phase 3 weight-loss efficacy data, TRIUMPH-4 and TRIUMPH-1 results show roughly double the weight reduction compared to STEP-1 data for semaglutide at its highest obesity dose. However, Ozempic has years of post-marketing safety data across millions of patients, established cardiovascular outcome trial results (SUSTAIN-6, SELECT), and full FDA approval. Retatrutide lacks that track record — it is investigational, Phase 3 safety data is still being characterized, and no NDA has been filed. The comparison is mechanistic and evidential, not a clinical recommendation. Research use only.
Why is retatrutide's weight loss higher than Ozempic?
The additional receptor arms are the mechanistic explanation. Semaglutide (Ozempic/Wegovy) activates GLP-1 receptors, which suppress appetite and slow gastric emptying. Retatrutide adds GIP receptor agonism — which improves insulin potentiation and may enhance the GLP-1 signal — and glucagon receptor agonism, which increases thermogenesis and energy expenditure. Adding the glucagon arm means the body is simultaneously suppressing caloric intake (GLP-1/GIP) and increasing caloric expenditure (glucagon), creating a larger net energy deficit. Retatrutide is for in-vitro and pre-clinical research only.
Does Titan sell Ozempic?
No. Titan Peptide Lab does not stock semaglutide (Ozempic or Wegovy). Ozempic is an FDA-approved prescription medication available through licensed pharmacies and prescribers — an entirely different supply channel from the RUO research market. Titan supplies retatrutide as a lyophilized research-use-only vial ($199.99) for in-vitro laboratory research.
Is retatrutide a replacement for Ozempic?
No — and this page does not position it that way. Ozempic is a physician-prescribed medication for type 2 diabetes. Retatrutide is an investigational compound supplied by Titan as a research-use-only material for laboratory research. They are in different regulatory categories, different supply chains, and different stages of clinical development. Any decision about diabetes or weight management treatment is a clinical matter between a patient and their prescribing physician — not a sourcing question for RUO compounds.
How does the COA differ for retatrutide vs a semaglutide research vial?
The critical COA check for retatrutide is C18 Lys26 acylation confirmation — the fatty diacid modification that enables the ~6-day half-life and multi-receptor pharmacology must be confirmed by high-resolution MS because a bare purity percentage cannot detect a missing or mis-positioned acyl chain. Semaglutide similarly carries a C18 fatty diacid at Lys26, but the specific acylation position and chain composition differ. Any retatrutide release sheet that does not document acylation identity is incomplete. Titan uses in-house lot-matched release sheets for every batch. See /how-to-verify-peptide-quality-coa/ for what the full COA checklist includes.

Related reading

Before you check out.